AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32765053
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic treatment (SAT)
Trial: 32765056
Drug: Mirogabalin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirogabalin (7.5 mg twice daily for moderate renal impairment; 7.5 mg once daily for severe renal impairment)
Trial: 32765156
Drug: Subspecialist treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subspecialist treatment for severe asthma
Trial: 32766469
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of nerve growth factor (NGF) into the right masseter muscle on days 0 and 2.
Trial: 32766469
Drug: Pain diaries
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain diaries completed twice daily from day 0 to day 30.
Trial: 32766725
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of ciprofloxacin 500 mg
Trial: 32766875
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg on days 1 and 15 of a 28-day cycle
Trial: 32766885
Drug: Histidine supplementation
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histidine supplementation at 12 g/d (Study 1)
Trial: 32766885
Drug: Histidine supplementation
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histidine supplementation at 16 g/d (Study 2)
Trial: 32766885
Drug: Histidine supplementation
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histidine supplementation (4, 8, and 12 g/d in Study 1)
Trial: 32766885
Drug: Histidine supplementation
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histidine supplementation (16 g/d in Study 2)
Trial: 32766961
Drug: Low-dose ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ticagrelor
Trial: 32768179
Drug: Bleeding leading
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleeding leading to a postoperative haemoglobin <70 g L
Trial: 32769075
Drug: Videoconferencing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconferencing and self-administered tests of functional mobility and strength
Trial: 32770263
Drug: CA6 rs17032907
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA6 rs17032907 gene variant (dominant model CC vs. TT)
Trial: 32770263
Drug: Genotype CC
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype CC and allele C presence
Trial: 32770704
Drug: Placement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of a rectal balloon catheter alongside the AAR catheter
Trial: 32770720
Drug: Budigalimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation; flat doses of 250 mg Q2W or 500 mg every four weeks (Q4W) in multihistology expansion cohort.
Trial: 32770720
Drug: Budigalimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation.
Trial: 32770720
Drug: Budigalimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab at various doses.
Trial: 32770845
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation conducted by a pharmacist
Trial: 32770954
Drug: Anti-TB chemotherapy
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TB chemotherapy
Trial: 32771020
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (RT) intervention, eighteen 1-h sessions
Trial: 32771088
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg orally twice daily for 4 weeks, followed by olaparib 300 mg twice daily and durvalumab 1.5 g intravenously every 4 weeks until disease progression.
Trial: 32771088
Drug: Olaparib and
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib and durvalumab combination treatment.
Trial: 32772323
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TTh) for 27.63 ± 3.64 weeks
Trial: 32772323
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TTh)
Trial: 32772769
Drug: CD19 CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19 CAR-T cells therapy
Trial: 32773447
Drug: DaxibotulinumtoxinA for
RxNorm normalized name: daxibotulinumtoxinA-lanm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DaxibotulinumtoxinA for Injection (DAXI) 40U, up to 3 treatments over a maximum of 84 weeks
Trial: 32773474
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir 800 mg once daily and etravirine 400 mg once daily or 200 mg twice daily
Trial: 32774419
Drug: Comprehensive Spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Spa Therapy using Therapeutic Radon-Sulfur Waters
Trial: 32775974
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dimethyl sulfide and D-limonene
Trial: 32776159
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride multilayer extended-release capsules (MPH-MLR) at doses of 10, 15, or 20 mg
Trial: 32776489
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment (n=10)
Trial: 32776489
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment (n=14)
Trial: 32776489
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (aPCC and/or rFVIIa)
Trial: 32776632
Drug: Trametinib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 1.5 mg daily and Sorafenib 200 mg twice daily
Trial: 32777064
Drug: Ixazomib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib (4 mg on days 1, 8, and 15 of a 28-day cycle, started on day +5)
Trial: 32777116
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/d for 21 days in combination with idarubicin and cytarabine chemotherapy
Trial: 32777335
Drug: 24 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 Gy single-dose radiation therapy (SDRT)
Trial: 32778095
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg BID followed by olaparib + durvalumab (1500 mg Q4W) + tremelimumab (75 mg IV Q4W) for 4 months, then durvalumab alone until progression or intolerable toxicity.
Trial: 32779863
Drug: Anakinra (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (subcutaneous daily injections starting at 2 mg/kg, increased up to 6 mg/kg if fever persisted)
Trial: 32780661
Drug: HFRT (43.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFRT (43.5 Gy in 15 fractions over 3 weeks with a boost of 8.7 Gy in three daily fractions)
Trial: 32781527
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of gemcitabine with cisplatin
Trial: 32781527
Drug: Inhibitor of
RxNorm normalized name: Membrane inhibitor of reactive lysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor of fibroblast growth factor receptor 2 (FGFR2)
Trial: 32781527
Drug: Immunotherapeutic drugs
RxNorm normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapeutic drugs
Trial: 32781541
Drug: R-CHOP (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) plus IT-MTX (intrathecal methotrexate) 12 mg, six cycles of R-CHOP and four fixed doses of IT-MTX.
Trial: 32782084
Drug: Amphetamine-type stimulant
RxNorm normalized name: AMPHETAMINE LIKE STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine-type stimulant positive patients
Trial: 32782084
Drug: Amphetamine-type stimulant
RxNorm normalized name: AMPHETAMINE LIKE STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine-type stimulant negative patients
Trial: 32786149
Drug: Corticosteroids and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and/or tacrolimus treatment for rejection
Trial: 32788120
Drug: Individualised thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised thromboprophylaxis protocol with augmented LMWH dosing, anti-Xa measurements, and twice-weekly ultrasonography screening for DVT
Trial: 32788205
Drug: TAK-164 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-164 (a second-generation investigational antibody-drug conjugate comprised of a human anti-GCC mAb conjugated to DGN549)
Trial: 32789591
Drug: Single-agent abemaciclib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent abemaciclib
Trial: 32789591
Drug: Real-world single-agent
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world single-agent chemotherapy (capecitabine, gemcitabine, eribulin, or vinorelbine)
Trial: 32790648
Drug: Oral nicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicotinamide riboside (NR) for 5 to 9 days
Trial: 32791158
Drug: Injection pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pressure monitoring during PNB
Trial: 32791158
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow rate (9.6 mL/min)
Trial: 32791158
Drug: Overall injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall injection pressure monitoring
Trial: 32791523
Drug: INSTI as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INSTI as a third agent
Trial: 32792226
Drug: Intrathecal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal recombinant human arylsulfatase A (rhASA) at 10, 30, or 100 mg every other week for 38 weeks (n=6 per cohort)
Trial: 32792226
Drug: Intrathecal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg (cohort 4, n=6)
Trial: 32792226
Drug: Intrathecal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg
Trial: 32792456
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy Sensory Instrument for Cognition, Consciousness and Awareness (MuSICCA)
Trial: 32792991
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment after 12 weeks
Trial: 32793403
Drug: Deferasirox film-coated
RxNorm normalized name: deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox film-coated tablets (FCT)
Trial: 32794142
Drug: Intravenous methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylphenidate (0.5-2.0 mg/kg)
Trial: 32795349
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus CapeOx (200 mg IV of sintilimab and 1000 mg/m2 of capecitabine and oxaliplatin)
Trial: 32797064
Drug: Non-compacted LV
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-compacted LV mass (median 14.0 [interquartile range 12.6-16.0] g/m2)
Trial: 32797101
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administrations (MDAs) and reactive focal mass drug administrations (rfMDAs) with annual indoor residual spraying (IRS) and long-lasting insecticidal nets (LLINs)
Trial: 32797101
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administrations (MDAs)
Trial: 32799036
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment in frontline therapy
Trial: 32799356
Drug: Extended duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended duration antibiotics
Trial: 32800381
Drug: Tafamidis meglumine
RxNorm normalized name: Tafamidis meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis meglumine 20 mg/d
Trial: 32800518
Drug: Tositumomab (TST)
DrugBank: Tositumomab (DB00081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tositumomab (TST) and iodine-131 tositumomab (I-131 TST) followed by CHOP treatment
Trial: 32800708
Drug: Intravenous antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antimicrobial exacerbation treatments
Trial: 32800802
Drug: Definitive (chemo)radiation
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definitive (chemo)radiation therapy for HPV-related OPC
Trial: 32801289
Drug: Serum brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum brain natriuretic peptide ≥ 66.0 pg/mL
Trial: 32802051
Drug: Dexmedetomidine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (bolus dose over 15 min after delivery for parturient group)
Trial: 32802051
Drug: Dexmedetomidine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (bolus administered intravenously upon completion of spinal anesthesia for nonpregnant women group)
Trial: 32802401
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/day, vitamin D 2000 IU/day, GAD-alum 20 μg on D15 and D45
Trial: 32802401
Drug: Placebo instead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo instead of Ibuprofen, vitamin D 2000 IU/day, GAD-alum 20 μg on D15 and D45
Trial: 32802401
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/day, vitamin D 2000 IU/day, GAD-alum 40 μg on D15 and D45
Trial: 32802401
Drug: Placebo instead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo instead of Ibuprofen, vitamin D 2000 IU/day, GAD-alum 40 μg on D15 and D45
Trial: 32802401
Drug: Ibuprofen, vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, vitamin D + GAD-alum
Trial: 32803633
Drug: Vantictumab plus
RxNorm normalized name: Vantictumab
DrugBank: Vantictumab (DB12956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vantictumab plus weekly paclitaxel 90 mg/m
Trial: 32804069
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Hypersomnia (CBT-H)
Trial: 32804101
Drug: Pimavanserin (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin (monotherapy or adjunctive therapy)
Trial: 32804101
Drug: Pimavanserin (monotherapy)
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin (monotherapy)
Trial: 32804101
Drug: Pimavanserin (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin (adjunctive therapy)
Trial: 32804590
Drug: Ripretinib 150
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ripretinib 150 mg once daily (n = 142)
Trial: 32805208
Drug: Levonorgestrel intrauterine
RxNorm normalized name: Levonorgestrel Intrauterine System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel intrauterine device (52 mg levonorgestrel, Mirena)
Trial: 32806876
Drug: vedolizumab 108
RxNorm normalized name: VEDOLIZUMAB 108MG/0.68ML INJ PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vedolizumab 108 mg SC every 2 weeks
Trial: 32806876
Drug: vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vedolizumab 300 mg IV every 8 weeks
Trial: 32807090
Drug: nvHAP prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nvHAP prevention bundle consisting of oral care, prevention of dysphagia-related aspiration, mobilization, stopping unnecessary proton pump inhibitors, and respiratory therapy.
Trial: 32807456
Drug: Obesity and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obesity and previous use of antiplatelet therapy
Trial: 32807717
Drug: High-dose weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose weekly carfilzomib, cyclophosphamide, and dexamethasone
Trial: 32808163
Drug: Ivabradine 2.5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 2.5-7.5 mg twice daily for 57 days
Trial: 32809030
Drug: Magnetic Seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Seizure Therapy (MST) at low frequency (25 Hz)
Trial: 32809030
Drug: Magnetic Seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Seizure Therapy (MST) at moderate frequency (50 or 60 Hz)
Trial: 32809030
Drug: Magnetic Seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Seizure Therapy (MST) at high frequency (100 Hz)
Trial: 32809030
Drug: Overall MST
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall MST treatment
Trial: 32809083
Drug: 3D printed
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D printed brace for acute treatment of DRF
Trial: 32809217
Drug: MK-1248 monotherapy
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1248 monotherapy (starting dose 0.12 mg, maximum dose 170 mg)
Trial: 32809217
Drug: MK-1248 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1248 with pembrolizumab (200 mg) combination therapy (maximum dose 60 mg)
Trial: 32809969
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg twice daily for 2 days, followed by 4 mg per day for 7 days
Trial: 32811969
Drug: Tocilizumab in
RxNorm normalized name: tocilizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab in combination with methotrexate
Trial: 32812818
Drug: Midostaurin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin plus chemotherapy
Trial: 32812942
Drug: 30-g rapidly-digesting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-g rapidly-digesting carbohydrate (RDC) drink consisting of maltodextrin and sucrose, administered after an 8-h fast.
Trial: 32813194
Drug: PR-PFD (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-PFD (600 mg bid)
Trial: 32813884
Drug: Other stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other stem cell-based interventions (e.g. mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, hematopoietic stem cells, and inducible pluripotent stem cells)
Trial: 32814465
Drug: Clinically significant
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically significant AA burden after treatment
Trial: 32814465
Drug: AA burden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA burden after treatment
Trial: 32816721
Drug: Oxfendazole oral
RxNorm normalized name: oxfendazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxfendazole oral suspension at 3, 7.5, and 15 mg/kg once daily for 5 days
Trial: 32816721
Drug: Single 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 3 mg/kg dose of oxfendazole after overnight fast
Trial: 32816721
Drug: Single 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 3 mg/kg dose of oxfendazole after consumption of a fatty breakfast
Trial: 32816723
Drug: Fluconazole treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole treatment, dosage not specified, duration not specified
Trial: 32816951
Drug: MEDI0562 (0.03,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks until disease progression or unacceptable toxicity.